Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris(University of Pittsburgh), Maura L. Gillison(The University of Texas MD Anderson Cancer Center), Makoto Tahara(National Cancer Center Hospital East), Francis P. Worden(Georgetown University), Mark Lynch(Fluidigm (United States)), Jérôme Fayette(Université Claude Bernard Lyon 1), Tamara Rordorf(Institut Gustave Roussy), Naomi Kiyota(Kobe University Hospital), Justin Kopit(Gdańsk Medical University), Nabil F. Saba(Emory University), Lisa Licitra(University of Milan), Lara Carmen Iglesias Docampo(Institut Gustave Roussy), James W. Shaw(University of Illinois Chicago), Everett E. Vokes(University of Chicago), A. Dimitrios Colevas(Cancer Institute (WIA)), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Manish Monga(Institut Gustave Roussy), George R. Blumenschein(The University of Texas MD Anderson Cancer Center), Robert I. Haddad(Georgetown University), William J. Geese(Institut Gustave Roussy), Stefan Kasper(Essen University Hospital), Caroline Even(Institut Gustave Roussy), J. Guigay(Centre Antoine Lacassagne)
Cited by 5,085
Related Papers
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
|Journal of Clinical Oncology|2011|3.6k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Incidence Trends for Human Papillomavirus–Related and –Unrelated Oral Squamous Cell Carcinomas in the United States
|Journal of Clinical Oncology|2008|1.6k